Organic Disease Presenting as a Psychiatric Syndrome
Postgrad Med 54:78, , 1973
Narcolepsy
NEJM 288:1156, Zarcone,V., 1973
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Prodromal Symptoms of Multiple Sclerosis in Primary Care
Ann Neurol 83:1162-1173, Disanto,G.,et al, 2018
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Clinicopath Conf, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
NEJM 360:1656-1665, Case 12-2009, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Multiple Sclerosis with Predominant, Severe Cognitive Impairment
Arch Neurol 66:1139-1143, Staff,N.,et al, 2009
Multiple Sclerosis and Cannabis: A Cognitive and Psychiatric Study
Neurol 71:164-169, Ghaffar,O. &Feinstein,A., 2008
Thalamic Atrophy and Cognition in Multiple Sclerosis
Neurol 69:1213-1223, Houtchens,M.K.,et al, 2007
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Cognitive Presentation of Multiple Sclerosis: Evidence for a Cortical Variant
JNNP 74:872-877, Zarei,M.,et al, 2003
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
The Influence of Cognitive Impairment on Driving Performance in Multiple Sclerosis
Neurol 56:1089-1094, Schultheis,M.R.,et al, 2001
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Serum Angiotensin-Converting Enzyme in Multiple Sclerosis
Arch Neurol 54:1012-1015, Constantinescu,C.S.,et al, 1997
Serial Neuropsychological Assess & Magnetic Resonance Imagingf Analysis in Multiple Sclerosis
Arch Neurol 54:1018-1025, Hohol,M.J.,et al, 1997
Clinicopath Conf
Demyelinating Disease, Case 8-1996, NEJM 334:715-720996., , 1996
Dementia in 2 Histologically Confirmed Cases of MS:One Isolated Dementia & One Assoc with Psychiatric Symptoms
JNNP 57:353-359, Fontaine,B.,et al, 1994
Information Processing Efficiency in Chronic Fatigue Syndromes and Multiple Sclerosis
Arch Neurol 50:301-304, DeLuca,J.,et al, 1993
Multiple Sclerosis Dementia
Neurol 42:696, Mendez,M.D.&Frey,W.F., 1992
Event-Related Potential P300 in MS, Relation to Magnetic Resonance Imaging and Cognitive Impairment
Arch Neurol 49:44-50, Honig,L.S.,et al, 1992
Cognitive Dysfunction in MS, II. Impact on Employment and Social Functioning
Neurol 41:692-696, Rao,S.M.,et al, 1991
Clinicopath Conf
Acute Multiple Sclerosis, Case Record 42-1990, NEJM 323:1123-1135990., , 1990
Cognitive Loss in Multiple Sclerosis
Arch Neurol 46:162-167, Franklin,G.M.,et al, 1989
Lyme Neuroborreliosis:Central Nervous System Manifestations
Neurol 39:753-759, Halperin,J.J.,et al, 1989
Disease Activity & Emotional State in Multiple Sclerosis
Ann Neurol 13:573-577, Dalos,N.P.,et al, 1983
Evoked Potentials in Neurological Diagnosis
BMJ 285:1678-1679, Mastaglia,F.L.,et al, 1982
Cognitive Function in Patients With Multiple Sclerosis
Arch Neurol 37:577-579, Peyser,J.M.,et al, 1980